Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

cial projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

References
1 Dohner H. Phase I/II study of volasertib (BI 6727), an intravenous Polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): results from the randomized phase II part for volasertib in combination with low-dose cytarabine (LDAC) versus LDAC monotherapy in patients with previously untreated AML ineligible for intensive treatment. Oral Presentation at ASH Annual Meeting and Exposition 2012.

2 The Leukemia and Lymphoma Society. Facts 2012. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf [Last Accessed: November 21, 2012]

3 Texas Oncology. Acute Myeloid Leukemia Induction, Overview. Available at: http://www.texasoncology.com/types-of-cancer/leukemia/acute-myeloid-leukemia/acute-myeloid-leukemia-induction/ [Last Accessed: November 21, 2012]

4 Texas Oncology. Acute Myeloid Leukemia Consolidation, Overview. Available at:

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... ... technology, CHICAGO, March 30 ... balloons and stents,to open a completely blocked coronary artery and restore ... attack when performed rapidly.,However, few hospitals can meet the 90-minute treatment ...
... drug appears ... unnecessary, ... improvements in percutaneous coronary,intervention (PCI) for patients with heart attack, among ... unwanted blood clotting. Now a new study has found that high,loading ...
Cached Medicine Technology:Is PCI Safe, Effective After Clot-Busters for Heart Attack? 2Is PCI Safe, Effective After Clot-Busters for Heart Attack? 3BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack 2BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack 3
(Date:4/24/2014)... Changes in managing patients before, during and after colorectal ... readmission rates, according to researchers who led a study ... practice, called enhanced recovery, is easier on patients before ... evacuation that are typically prescribed. After surgery, patients are ... possible, leading to faster recoveries. , Among findings published ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... is looking to give exercise enthusiasts the extra nudge ... shows that a cyber buddy can help. , The ... Journal , is the first to indicate that although ... exercise, a software-generated partner also can be effective. , ... can still motivate people to give greater effort while ...
Breaking Medicine News(10 mins):Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2
... compounds may explain the increased cases , FRIDAY, Nov. 6 ... volcano puts people at higher risk of getting a type ... might be related to cancer, but researchers suspect that the ... Researchers are also unsure of why thyroid cancer rates are ...
... , LAS VEGAS, Nov. 6 Cord Blood America, ... stem cell preservation company ( http://www.cordblood-america.com ... stem cells, a biological insurance policy for families nationwide ... laboratory in Las Vegas, and its recently refiled S1 ...
... ... NTSB Mandatory Sleep Apnea Testing Recommendations Are Expected To Become A Law ... Tracking Industry, A Sleep Apnea Lab Testing Could Cost About $2,000 With ... Diagnosed Apnea Patients Can Not Tolerate Standard CPAP Treatment. Dr. Jin Zhou ...
... Kids, American Cancer Society, American Cancer Society Cancer Action ... Legacy Foundation , WASHINGTON, Nov. 5 In ... in Kentucky today rejected a motion by tobacco companies ... the U.S. Food and Drug Administration (FDA) the power ...
... has Important Implications for Genetic Testing and Individualized Medicine , ... long QT syndrome (LQTS) study published in the ... genetic testing,s role in diagnosing disease, according to the senior ... pediatric cardiologist at Mayo Clinic, Dr. Ackerman directs Mayo,s Long ...
... Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today ... the third quarter of 2009 compared to a net,loss of $46.4 ... Net income for the nine months ended September 30, 2009 ... of,$163.8 million, or $3.22 diluted share, for the first nine months ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Cord Blood America Updates Advantages of Las Vegas Laboratory in Analyst Interview; Explains Recent S1 Filing 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 3Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 4Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 5Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 2Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 4Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 5Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 6Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 7Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 8Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 9Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 10Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 11Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 12Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 13Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 14Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 15Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 16Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 17Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 18
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches....
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Flattened 13 mm "Graefe type" hook, with 1.5 mm oval hole. Flat serrated handle with polished finish. Overall length: 5.6 inches....
Medicine Products: